PMID- 25824849
OWN - NLM
STAT- MEDLINE
DCOM- 20160127
LR  - 20150427
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 352
IP  - 1-2
DP  - 2015 May 15
TI  - HLA-DRB1 does not have a role in clinical response to interferon-beta among 
      Iranian multiple sclerosis patients.
PG  - 37-40
LID - S0022-510X(15)00134-3 [pii]
LID - 10.1016/j.jns.2015.03.004 [doi]
AB  - BACKGROUND & OBJECTIVES: The role of human leukocyte antigen (HLA) in clinical 
      response to immunotherapy is not completely known. In this study we evaluated the 
      relationship between HLA-DRB1 genotype, which has been proved to be more common 
      in Iranian MS patients, and clinical response to interferon-beta (IFNbeta), which is 
      the most common immunotherapy for relapsing-remitting MS. DESIGN AND SETTING: In 
      this study 68 Iranian patients with confirmed diagnosis of RRMS who had been 
      referred to and admitted in Neurology Department of Amiralam and Khatam Hospitals 
      in Tehran were selected. Patients were followed prospectively for 2 years since 
      initiation of therapy and clinical data, including EDSS scores were recorded 
      every 3 months. MRI was performed at the time of diagnosis and each year. 
      METHODS: HLA-DRB1 typing was performed by polymerase chain reaction (PCR) for all 
      patients and data was analyzed by STATA 12th edition. RESULTS: There were 47 
      (69.1%) responders and 21 (30.9%) non-responders. These two groups were 
      demographically and clinically comparable. Fisher's exact test did not show any 
      difference between HLA-DRB1 allele frequencies in responders and non-responders. 
      CONCLUSIONS: Our findings confirmed the lack of association between HLA-DRB1 and 
      clinical response to IFNbeta among MS patients as previous studies had done.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Samadzadeh, Sara
AU  - Samadzadeh S
AD  - Shefa Neurosciences Research Center, Tehran, Islamic Republic of Iran; Tehran 
      University of Medical Sciences, Neurology Department, Tehran, Islamic Republic of 
      Iran.
FAU - Tabibian, Elnaz
AU  - Tabibian E
AD  - Tehran University of Medical Sciences, Neurology Department, Tehran, Islamic 
      Republic of Iran.
FAU - Sabokbar, Tayebeh
AU  - Sabokbar T
AD  - Neurology & Neurosciences Research Center, Qom University of Medical Sciences, 
      Qom, Islamic Republic of Iran; Tehran University of Medical Sciences, Department 
      of Medical Genetics, Cancer Institute, Tehran, Islamic Republic of Iran.
FAU - Shakoori, Abbas
AU  - Shakoori A
AD  - Tehran University of Medical Sciences, Department of Medical Genetics, Cancer 
      Institute, Tehran, Islamic Republic of Iran.
FAU - Dehgolan, Shahram Rahimi
AU  - Dehgolan SR
AD  - Tehran University of Medical Sciences, Neurology Department, Tehran, Islamic 
      Republic of Iran.
FAU - Armaki, Saeed Azad
AU  - Armaki SA
AD  - Shefa Neurosciences Research Center, Tehran, Islamic Republic of Iran.
FAU - Aslanbeigi, Bahram
AU  - Aslanbeigi B
AD  - Shefa Neurosciences Research Center, Tehran, Islamic Republic of Iran.
FAU - Abolfazli, Roya
AU  - Abolfazli R
AD  - Shefa Neurosciences Research Center, Tehran, Islamic Republic of Iran; Tehran 
      University of Medical Sciences, Neurology Department, Tehran, Islamic Republic of 
      Iran. Electronic address: abolfazl@sina.tums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150309
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Immunologic Factors)
RN  - 77238-31-4 (Interferon-beta)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Follow-Up Studies
MH  - Genotype
MH  - HLA-DRB1 Chains/*genetics
MH  - Humans
MH  - Immunologic Factors/therapeutic use
MH  - Immunotherapy/methods
MH  - Interferon-beta/administration & dosage/*therapeutic use
MH  - Iran
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*drug 
      therapy/*genetics/pathology/physiopathology
MH  - Polymerase Chain Reaction
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Frequencies in responders and non-responders
OT  - HLA-DR beta-Chains
OT  - Interferon-beta
OT  - Iran
OT  - Multiple sclerosis
EDAT- 2015/04/01 06:00
MHDA- 2016/01/28 06:00
CRDT- 2015/04/01 06:00
PHST- 2014/10/04 00:00 [received]
PHST- 2015/02/09 00:00 [revised]
PHST- 2015/03/02 00:00 [accepted]
PHST- 2015/04/01 06:00 [entrez]
PHST- 2015/04/01 06:00 [pubmed]
PHST- 2016/01/28 06:00 [medline]
AID - S0022-510X(15)00134-3 [pii]
AID - 10.1016/j.jns.2015.03.004 [doi]
PST - ppublish
SO  - J Neurol Sci. 2015 May 15;352(1-2):37-40. doi: 10.1016/j.jns.2015.03.004. Epub 
      2015 Mar 9.